LINC02454 promotes thyroid carcinoma progression via upregulating HMGA2 through CREB1
The FASEB Journal · 2023
DOI: 10.1096/fj.202301070rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Yan Cao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Third Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: MicroRNAs, Thyroid Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: General project of Hunan Natural Science Foundation in 2022, Hainan Provincial NaturalScience Foundation of China, Regulation of LncRNA RP11-221N13.3 to promote thyroid cancer proliferation and invasion.
Abstract (Originalsprache)
Thyroid carcinoma (THCA) is the most common malignancy in the endocrine system. Long intergenic non‐coding RNA 2454 (LINC02454) exhibits an HMGA2‐like expression pattern, but their relationship and roles in THCA are largely unknown. The present purpose was to delineate the roles of LINC02454 in THCA progression and its molecular mechanisms. We collected THCA tissues from patients and monitored patient survival. THCA cell colony formation, migration, and invasion were evaluated. Metastasis was evaluated by examining EMT markers through Western blotting. Gene interaction was determined with ChIP, RIP, RNA pull‐down, and luciferase activity assays. A mouse model of a subcutaneous tumor was used to determine the activity of LINC02454 knockdown in vivo. We found that LINC02454 was highly expressed in THCA, and its upregulation was associated with poor survival. The knockdown of LINC02454 repressed colony formation, migration, and invasion. Moreover, loss of LINC02454 inhibited tumor growth and metastasis in mice. HMGA2 promoted LINC02454 transcription via binding to the LINC02454 promoter, and silencing of HMGA2 suppressed malignant behaviors through downregulation of LINC02454. HMGA2 was a novel functional target of LINC02454 in THCA cells, and knockdown of LINC02454‐mediated anti‐tumor effects was reversed by HMGA2 overexpression. Mechanically, LINC02454 promoted CREB1 phosphorylation and nuclear translocation, and CREB1 was subsequently bound to the HMGA2 promoter to facilitate its expression. LINC02454 cis‐regulates HMGA2 transcription via facilitating CREB1 phosphorylation and nuclear translocation, and, in turn, HMGA2 promotes LINC02454 expression, thus accelerating thyroid carcinoma progression. Our results support therapeutic targets of LINC02454 and HMGA2 for THCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The Third Xiangya Hospital, Central South University, Changsha, China.
- Department of clinical medicine, Hunan University of Chinese Medicine, Changsha, China.
- Department of Tumor Chemotherapy, Haikou People's Hospital, Haikou, China.
ORCID-Profile: Yan Cao, Jian Li, Yongliang Du, Yuxuan Sun, Le Liu, Hao Fang, Yan Liang, Shanshan Mao
Förderung
- General project of Hunan Natural Science Foundation in 2022
- Hainan Provincial NaturalScience Foundation of China
- Regulation of LncRNA RP11-221N13.3 to promote thyroid cancer proliferation and invasion
- Role and mechanism of LncRNA LINC2454 cis-regulating HMGA2 contributes to thyroid carcinoma malignant progression
Zitieren
APA
Cao, Y., Li, J., Du, Y., Sun, Y., Liu, L., Fang, H., Liang, Y., & Mao, S. (2023). LINC02454 promotes thyroid carcinoma progression via upregulating HMGA2 through CREB1. The FASEB Journal. https://doi.org/10.1096/fj.202301070rr
Vancouver
Cao Y, Li J, Du Y, Sun Y, Liu L, Fang H, et al. LINC02454 promotes thyroid carcinoma progression via upregulating HMGA2 through CREB1. The FASEB Journal. 2023. doi:10.1096/fj.202301070rr
BibTeX
@article{Cao2023,
author = {Cao, Yan and Li, Jian and Du, Yongliang and Sun, Yuxuan and Liu, Le and Fang, Hao and Liang, Yan and Mao, Shanshan},
title = {LINC02454 promotes thyroid carcinoma progression via upregulating HMGA2 through CREB1},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202301070rr}
}
EUVIMED